$Agenus(AGEN.US) fell back -17% today, which is actually profit-taking after Monday's doubling surge—it announced three-year Phase 1b data for the botensilimab plus balstilimab combination in refractory colorectal cancer, with a median overall survival of 21.2 months, causing it to surge directly by 100% on Monday, and HC Wainwright maintained a Buy rating and raised the target price to $30.

The current dilemma is: after the data-driven doubling, it has pulled back significantly. Is this normal digestion of profit-taking, presenting a buying opportunity on dips, or is it a one-time data catalyst that's now exhausted with no follow-up? It looks more like the former—the real next catalyst will be waiting for the registration pathway and subsequent clinical updates. Pulling back to a level with no new news is actually an observation window, but with such volatility in small-cap Biotech, don't go too heavy on the position.